FoRx Therapeutics
PrivateLast Round
Series A
Dec 18, 2025
Total Funding Raised
$60.85M
Company Overview
FoRx Therapeutics operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Series A round in December 2025.
FoRx Therapeutics is a biotechnology company that develops a new generation of first-in-class oral small molecule cancer drugs focusing on novel DNA Replication Stress pathways.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
FoRx Therapeutics Comparables
Compare FoRx Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 858 Therapeutics | 88% | |
| Eisbach Bio GmbH | 82% | |
| Nodus Oncology | 81% |
For institutional investors. Book with your work email.
FoRx Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 18, 2025 | ||||
| Seed | Apr 22, 2020 |
For institutional investors. Book with your work email.
FoRx Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Omega Funds | Seed |
| EQT Life Sciences | Seed, Series A |
| M Ventures | Series A, Seed |
| Pfizer Ventures | Seed, Series A |
| Pfizer | Seed, Series A |
| Pfizer Ventures | Seed, Series A |
| M Ventures | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 26, 2026
FORX-428 shows potential for best-in-class PARG inhibition.
- Mar 26, 2026
Presented preclinical data for FORX-428 at ACS Spring 2026.
For institutional investors. Book with your work email.
FoRx Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about FoRx Therapeutics's valuation, stock price, and market status.
Is FoRx Therapeutics a public or private company?
FoRx Therapeutics is a private company.
What is the current stock price of FoRx Therapeutics?
FoRx Therapeutics is a private company, so its shares have no public market price. Caplight tracks FoRx Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is FoRx Therapeutics worth (valuation)?
Valuation information for FoRx Therapeutics is not publicly available.
Can I buy FoRx Therapeutics stock?
FoRx Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was FoRx Therapeutics's last funding round?
FoRx Therapeutics's most recent funding round was Series A on December 18, 2025.
Who are the main investors in FoRx Therapeutics?
Key investors in FoRx Therapeutics include Omega Funds, M Ventures, M Ventures.
Will FoRx Therapeutics IPO soon?
No public IPO plans have been announced for FoRx Therapeutics.
How can I track FoRx Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in FoRx Therapeutics's shares on secondary markets.